Trade Emergent BioSolutions Inc. - EBS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 5.3 |
| Open | 5.18 |
| 1-Year Change | 140.93% |
| Day's Range | 5.18 - 5.65 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 5.30 | 0.38 | 7.72% | 4.92 | 5.37 | 4.88 |
| Apr 23, 2025 | 4.93 | 0.07 | 1.44% | 4.86 | 5.06 | 4.82 |
| Apr 22, 2025 | 4.69 | 0.18 | 3.99% | 4.51 | 4.78 | 4.40 |
| Apr 21, 2025 | 4.50 | 0.10 | 2.27% | 4.40 | 4.54 | 4.38 |
| Apr 17, 2025 | 4.58 | 0.05 | 1.10% | 4.53 | 4.65 | 4.44 |
| Apr 16, 2025 | 4.57 | 0.03 | 0.66% | 4.54 | 4.61 | 4.44 |
| Apr 15, 2025 | 4.58 | 0.10 | 2.23% | 4.48 | 4.61 | 4.40 |
| Apr 14, 2025 | 4.54 | 0.04 | 0.89% | 4.50 | 4.63 | 4.29 |
| Apr 11, 2025 | 4.32 | 0.19 | 4.60% | 4.13 | 4.48 | 4.09 |
| Apr 10, 2025 | 4.22 | -0.22 | -4.95% | 4.44 | 4.49 | 4.16 |
| Apr 9, 2025 | 4.67 | 0.61 | 15.02% | 4.06 | 4.75 | 3.99 |
| Apr 8, 2025 | 4.23 | -0.36 | -7.84% | 4.59 | 4.63 | 4.17 |
| Apr 7, 2025 | 4.30 | 0.04 | 0.94% | 4.26 | 4.78 | 4.10 |
| Apr 4, 2025 | 4.44 | -0.10 | -2.20% | 4.54 | 4.66 | 4.29 |
| Apr 3, 2025 | 4.78 | -0.01 | -0.21% | 4.79 | 5.03 | 4.72 |
| Apr 2, 2025 | 5.12 | 0.56 | 12.28% | 4.56 | 5.31 | 4.56 |
| Apr 1, 2025 | 4.72 | -0.03 | -0.63% | 4.75 | 4.92 | 4.57 |
| Mar 31, 2025 | 4.83 | -0.01 | -0.21% | 4.84 | 5.39 | 4.50 |
| Mar 28, 2025 | 4.62 | -0.26 | -5.33% | 4.88 | 4.88 | 4.50 |
| Mar 27, 2025 | 4.87 | -0.22 | -4.32% | 5.09 | 5.09 | 4.58 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Emergent BioSolutions Company profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, it offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, the company offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. Emergent BioSolutions Inc. has a development and manufacturing agreement with Novavax Inc. for coronavirus disease vaccine candidate. The company was founded in 1998 and is headquartered in Gaithersburg, Maryland.| Industry: | Pharmaceuticals (NEC) |
400 Professional Dr, Suite 400
GAITHERSBURG
MARYLAND 20879
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com